A retrospective study of outpatient cost in patients with end stage lung cancer during the last six months of their life.

Postgraduate Thesis uoadl:1315690 336 Read counter

Unit:
Κατεύθυνση Κλινική Φαρμακευτική
Library of the School of Science
Deposit date:
2015-11-11
Year:
2015
Author:
Καμπούκου Αγγελική
Supervisors info:
Σοφία Μαρκαντώνη-Κυρούδη Καθηγήτρια
Original Title:
Αναδρομική μελέτη καταγραφής του εξωνοσοκομειακού κόστους ασθενών με καρκίνο του πνεύμονα τελικού σταδίου κατά τους τελευταίους έξι μήνες της ζωής τους.
Languages:
Greek
Translated title:
A retrospective study of outpatient cost in patients with end stage lung cancer during the last six months of their life.
Summary:
Lung cancer is the leading cause of cancer-related death in Europe and
worldwide and still remains one of the biggest public health problems. Due to
its high incidence and mortality and the parallel increase in the cost of
treatment, lung cancer exerts a significant societal and healthcare-related
economic burden both on a national level and worldwide. The evaluation of
outpatient treatment costs of lung cancer in Greece is a necessary first step
for the assessment of the direct medical costs of lung cancer, in order to
rationalize pharmaceutical expenditure on a national level. This retrospective
study was conducted at the Oncology unit of the 3rd Internal Medicine
University Department of the SOTIRIA General Hospital. A total of 144 adult
patients with terminal stage lung cancer, who died between September 2011 and
June 2014, was included. All the outpatient services during the last six months
of life were recorded and their corresponding direct costs were estimated
through the Greek National Health System (E.O.P.Y.Y.). Outpatient costs
included the costs of all tests and medical interventions, radiotherapy and
concomitant medication administered to patients in addition to chemotherapy.
Outpatient costs per patient were calculated for each month and for the entire
six-month period under investigation. The total cost of outpatient services for
all patients amounted to 417.634,53€.Concomitant medication was responsible for
the largest percentage of total outpatient expenditures accounting for
246.490,25€ (59%), followed by tests and medical interventions (86.009,10€) and
finally by radiotherapy (85.135,00€). The total cost of outpatient services
showed an upward trend with the highest value being observed during the 4th
month (85.894,01€)while it decreased during the 6th month (31.238,35€). The
mean monthly cost of outpatient services per patientwas also highest during the
4thmonth (596,4862€). Moreover, the highest percentage of pharmaceutical
expenditure per patient was attributed to erythropoiesis and granulocyte colony
stimulating factors accounting for 131,621.70€. By evaluating the results of a
parallel retrospective study that examined the costs of inpatient services for
the same population under investigation, the highest overall cost for lung
cancer care was observed during the last two months of life. In conclusion, the
combined findings of both studies demonstrate that the direct medical costs of
patients with end-stage lung cancer in Greece are substantial. Our findings
provide the groundwork forfurther studies on a national level, evaluating other
types of costs such as the indirect costs of lung cancer.
Keywords:
Lung cancer, Outpatient cost, Tests, Radiotherapy, Concomitant medication
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
92
Number of pages:
Χ, 77
File:
File access is restricted.

document.pdf
2 MB
File access is restricted.